Genetic Causes of Familial Hypercholesterolemia

Status Recruiting

Clinical Trial Summary

Familial hypercholesterolemia (FH) is a common disease. The genetic background to FH is not yet fully understood. In the present prospective cohort study we aim to study the association between different clinical characteristics, gene mutations and prognosis.

Clinical Trial Description

In this prospective observational cohort study of patients with high clinical suspicion of familial hypercholesterolemia (FH) we aim to study the association between different clinical characteristics, gene mutations and prognosis. The included patients will undergo physical examination and extended blood sampling. DNA will be extracted and used for both whole genome sequencing and investigation of both known- , unknown- and suspected mutations associated with FH. The patients will be followed in for 15 years in the Swedish patients registry and the Swedish cause of death registry. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04101149
Study type	Observational
Source	Region Örebro County
Contact	Anna M Nordenskjöld, MD, PhD
Phone	+46 19 6021000
Email	anna.nordenskjold@regionorebrolan.se
Status	Recruiting
Phase
Start date	September 1, 2019
Completion date	December 2045

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT05284513` - Collaborative Approach to Reach Everyone With Familial Hypercholesterolemia (CARE-FH)	N/A
Enrolling by invitation	`NCT05271305` - Pilot Study for a National Screening for Familial Hypercholesterolemia
Completed	`NCT02750527` - Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany
Not yet recruiting	`NCT00924339` - Soy Food Intervention Trial	N/A
Withdrawn	`NCT00751608` - Effect of APL180 on Endothelial Function in Familial Hypercholesterolemia Patients	Phase 2
Terminated	`NCT00079846` - Implitapide in Patients With Homozygous Familial Hypercholesterolemia (HoFH) on Maximal Concurrent Lipid-Lowering Therapy	Phase 2
Completed	`NCT02624869` - Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia)	Phase 3
Recruiting	`NCT05758779` - The Danish Familial Hypercholesterolemia Organized Coronary Screening Trial	N/A
Enrolling by invitation	`NCT04929457` - Evaluation of a Digiphysical Screening Method to Identify and Diagnose Familial Hypercholesterolemia
Not yet recruiting	`NCT04455581` - A Study to Determine the Safety, Tolerability, and Efficacy of SHR-1209 in Patients With Familial Hypercholesterolemia	Phase 2
Completed	`NCT00943306` - Long Term, Follow-on Study of Lomitapide in Patients With Homozygous Familial Hypercholesterolemia	Phase 3
Completed	`NCT02462655` - Effects of LDL Apheresis System on the Expression of Genes Involved in Lipoprotein Metabolism and Inflammation in Homozygotes for Familial Hypercholesterolemia	N/A
Terminated	`NCT00079859` - Implitapide in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) on Maximal Concurrent Lipid-Lowering Therapy	Phase 2
Recruiting	`NCT05066932` - Advanced Lipoproptein Profiling and Cardiovascular Risk Stratification in Familial Hypercholesterolemia
Not yet recruiting	`NCT04958629` - A Prospective Cohort Study on Familial Hypercholesterolemia in Health Examination Population
Completed	`NCT02709850` - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS ANGPTL3-LRx in Healthy Volunteers With Elevated Triglycerides and Participants With Familial Hypercholesterolemia	Phase 1
Active, not recruiting	`NCT03832985` - Pediatric Reporting of Adult-Onset Genomic Results	Early Phase 1
Terminated	`NCT02013713` - French Observatory of Familial Hypercholesterolemia in Cardiology
Recruiting	`NCT02009345` - Familial Hypercholesterolemia Canada / Hypercholesterolemie Familiale Canada
Terminated	`NCT03331666` - Impact of LDL-cholesterol Lowering on Platelet Activation	Phase 4